IGF-1R/mTOR targeted therapy for ewing sarcoma: A meta-analysis of five IGF-1R-related trials matched to proteomic and radiologic predictive biomarkers

Hesham M. Amin, Ajaykumar C. Morani, Najat C. Daw, Salah Eddine Lamhamedi-Cherradi, Vivek Subbiah, Brian A. Menegaz, Deeksha Vishwamitra, Ghazaleh Eskandari, Bhawana George, Robert S. Benjamin, Shreyaskumar Patel, Juhee Song, Alexander J. Lazar, Wei Lien Wang, Razelle Kurzrock, Alberto Pappo, Peter M. Anderson, Gary K. Schwartz, Dejka Araujo, Branko CuglievanRavin Ratan, David McCall, Sana Mohiuddin, John A. Livingston, Eric R. Molina, Aung Naing, Joseph A. Ludwig

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Abstract

Background: Ten to fourteen percent of Ewing sarcoma (ES) study participants treated nationwide with IGF-1 receptor (IGF-1R)-targeted antibodies achieved tumor regression. Despite this success, low response rates and short response durations (approximately 7-weeks) have slowed the development of this therapy. Methods: We performed a meta-analysis of five phase-1b/2 ES-oriented trials that evaluated the anticancer activity of IGF-1R antibodies +/− mTOR inhibitors (mTORi). Our meta-analysis provided a head-to-head comparison of the clinical benefits of IGF-1R antibodies vs. the IGF-1R/mTOR-targeted combination. Available pretreatment clinical samples were semi-quantitatively scored using immunohistochemistry to detect proteins in the IGF-1R/PI3K/AKT/mTOR pathway linked to clinical response. Early PET/CT imaging, obtained within the first 2 weeks (median 10 days), were examined to determine if reduced FDG avidity was predictive of progression-free survival (PFS). Results: Among 56 ES patients treated at MD Anderson Cancer Center (MDACC) with IGF-1R antibodies, our analysis revealed a significant ~two-fold improvement in PFS that favored a combination of IGF-1R/mTORi therapy (1.6 vs. 3.3-months, p = 0.042). Low pIGF-1R in the pretreatment specimens was associated with treatment response. Reduced total-lesion glycolysis more accurately predicted the IGF-1R response than other previously reported radiological biomarkers. Conclusion: Synergistic drug combinations, and newly identified proteomic or radiological biomarkers of IGF-1R response, may be incorporated into future IGF-1R-related trials to improve the response rate in ES patients.

Original languageEnglish
Article number1768
Pages (from-to)1-17
Number of pages17
JournalCancers
Volume12
Issue number7
DOIs
StatePublished - Jul 2020
Externally publishedYes

Keywords

  • Biological therapies
  • Biomarker
  • Drug response
  • Ewing sarcoma
  • PET/CT
  • PIGF-1R

Fingerprint

Dive into the research topics of 'IGF-1R/mTOR targeted therapy for ewing sarcoma: A meta-analysis of five IGF-1R-related trials matched to proteomic and radiologic predictive biomarkers'. Together they form a unique fingerprint.

Cite this